FDA Approves Daiichi’s Savaysa, But Not For AF Patients With Normal Kidney Function
This article was originally published in The Pink Sheet Daily
Executive Summary
The Japanese pharma scored an approval of its oral anticoagulant, but is at a disadvantage to competition due to a label that restricts use to patients with renal impairment.
You may also be interested in...
Edoxaban Review ‘Not About Comparative Efficacy,’ FDA Says
Structured benefit/risk framework requires consideration of current treatment options, agency says in asking its cardio-renal advisory committee to consider the existence of three other novel anticoagulants when weighing the poor efficacy seen with Daiichi’s Factor Xa inhibitor in a large patient subgroup.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.